Compare HXHX & CMMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HXHX | CMMB |
|---|---|---|
| Founded | 2003 | 2004 |
| Country | China | Israel |
| Employees | N/A | N/A |
| Industry | Trucking Freight/Courier Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.0M | 13.8M |
| IPO Year | 2025 | N/A |
| Metric | HXHX | CMMB |
|---|---|---|
| Price | $0.51 | $1.69 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $26.50 |
| AVG Volume (30 Days) | ★ 17.4M | 85.1K |
| Earning Date | 02-18-2026 | 03-02-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 1.80 | N/A |
| EPS | ★ 0.30 | N/A |
| Revenue | ★ $34,088,144.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $1.69 | ★ N/A |
| Revenue Growth | ★ 32.57 | N/A |
| 52 Week Low | $0.33 | $1.60 |
| 52 Week High | $6.29 | $8.80 |
| Indicator | HXHX | CMMB |
|---|---|---|
| Relative Strength Index (RSI) | 43.88 | 33.76 |
| Support Level | $0.47 | $1.70 |
| Resistance Level | $0.62 | $1.85 |
| Average True Range (ATR) | 0.10 | 0.15 |
| MACD | -0.01 | 0.02 |
| Stochastic Oscillator | 5.73 | 22.50 |
Haoxin Holdings Ltd is engaged in the logistics industry, including container provider of temperature-controlled truckload service and urban delivery services in China, freight forwarding, cold chain transportation and other businesses. The types of goods involved are all kinds of new energy materials that require low temperature, heat preservation, and constant temperature, electronic products, medicines, meat, fruits, vegetables and others.
Chemomab Therapeutics Ltd is a clinical-stage biotech company, focusing on the discovery and development of therapeutics for fibrosis-related diseases with large unmet needs. The company's candidate, CM-101, is a monoclonal antibody that targets CCL24 and was shown to interfere with the underlying biology of liver, skin, and lung fibrosis using a novel and differentiated mechanism of action. CM-101 has demonstrated the potential to treat multiple severe and life-threatening fibrotic and inflammatory diseases. It is advancing three Phase 2 clinical trials in parallel for CM-101, treating rare fibrotic conditions.